WATERDROP FILES ANNUAL REPORT ON FORM 20-F FOR FISCAL YEAR 2024
- 72
PR Newswire
BEIJING, April 25, 2025
BEIJING, April 25, 2025 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission ("SEC") on April 25, 2025. The annual report can be accessed on the Company's investor relations website at https://ir.waterdrop-inc.com as well as the SEC's website at http://www.sec.gov.
The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to the Company's IR Department at [email protected].
About Waterdrop Inc.
Waterdrop Inc. (NYSE: WDH) is a leading technology platform dedicated to insurance and healthcare service with a positive social impact. Founded in 2016, with the comprehensive coverage of Waterdrop Insurance Marketplace and Waterdrop Medical Crowdfunding, Waterdrop aims to bring insurance and healthcare service to billions through technology. For more information, please visit www.waterdrop-inc.com.
For investor inquiries, please contact:
Waterdrop Inc.
[email protected]
View original content:https://www.prnewswire.com/news-releases/waterdrop-files-annual-report-on-form-20-f-for-fiscal-year-2024-302438304.html
SOURCE Waterdrop Inc.

PR Newswire's news distribution, targeting, monitoring and marketing solutions help you connect and engage with target audiences across the globe.
- Thunder Power Holdings, Inc. Provides Updates
- DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceutical Services
- Quanterix to Present at Goldman Sachs Global Healthcare Conference
- Immix Biopharma Attends FDA CEO Forum in Washington DC
- Soligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials
- Bango 2024 Full Year Results and Outlook